PRKCG and ocular melanoma: Western blot assay, as well as double immunostaining of p-PKCγ and Tubulin III further showed that p-PKCγ was significantly increased in 30% OM treated cells, suggesting that p-PKCγ is activated in differentiated N2a cells (Fig. 2b,c).